The first patient has been dosed in a Phase 1 clinical trial testing the viability of QRL-201 for treating #ALS. The experimental therapy increases production of stathmin-2, a protein neeeded for neuronal growth and repair. buff.ly/43UkFuE #amyotrophiclateralsclerosis

Our CSO Dan Elbaum recently presented on QRL-201, one of QurAlis' lead programs in #ALS at the 2023 #TargetALS conference. Dan's talk was entitled, "QRL-201: A #Stathmin-2 Splice-switching #ASO." #precisionmedicine #neurodegenerativediseases

We're honored to share that AngelaGenge, QurAlis' CMO, has been named the first international recipient of the Muscular Dystrophy Association Wings Over Wall Street Diamond Award. This award is given annually to a scientific leader dedicated to the eradication of #ALS. bit.ly/43sjBgD

Thank you to conference sponsor QurAlis for your ongoing support of #LongwoodHealthcareLeaders. We’re thrilled to host Kasper Roet as he discusses advances in #neurosciences at Massachusetts Institute of Technology (MIT).

Tonight I want to put this into the world and see what happens: I hope that you had a great day, are with people you love, are doing something you love, or are just celebrating being here. Good night moon.

Our CEO & founder Kasper Roet (2nd fr r) in “The Innovation Gap: Dissecting Emerging Modalities and Mechanisms for Treating CNS Diseases” panel today at Mass General Brigham #WMIF2023 hosted by Mass General Brigham Innovation presented by Bank of America News. #ALS #precisionmedicine #neurodegenerativediseases

QurAlis' CMO AngelaGenge delivering one of four presentations at the Canadian Neurological Sciences Federation annual meeting 2023 in Banff. #ALS #precisionmedicine #neurodegenerativediseases

QurAlis soon could extend its ALS Phase 1 safety trial of QRL-201 in countries including in Germany, Belgium, the Netherlands, and Ireland. buff.ly/3NctVCE #ALS #ALSNewsToday #amyotrophiclateralsclerosis #livingwithALS #ALSresearch

👇🏽

QurAlis is excited to announce a collaboration with Unlearn.AI to accelerate and optimize our clinical program in #ALS with Unlearn's advanced generative #AI technology. Read more here bit.ly/3pql7RP #precisionmedicine #neurodegenerativediseases

QurAlis in the news! Excited to have QurAlis and our CEO and co-founder Kasper Roet featured in the @NatureBiotechnology article about #ALS drug development and biomarkers. #precisionmedicine #neurodegenerativediseases bit.ly/44gM3mg

One of the great moments during our BioLabs opening in #Paris this week Hôtel-Dieu AP-HP Meeting Jérôme Monceaux, the inspiring founder of Enchanted Tools and their creation #Mirokai, an animated character/#robot for healthcare applications, together with minister Sylvie Retailleau

QurAlis is proud to sponsor #ENCALS23. Wishing all a most successful meeting as we work toward conquering #ALS and other #neurodegenerativediseases. #precisionmedicine bit.ly/3rjUQ8p

QurAlis at #ENCALS23! Clinical team members Kristiana Salmon and @ClaridaMartinez presented a poster on our QRL-201 ANQUR clinical trial - the 1st-ever study to evaluate a therapy that rescues #STMN2 expression in #ALS patients. #precisionmedicine #neurodegenerativediseases

QurAlis at #ENCALS23! QurAlis' chief medical officer AngelaGenge moderated the Therapeutic Session. #ALS #precisionmedicine #neurodegenerativediseases

This photo is from October 2017. Two months after I was diagnosed with ALS. On the outside, I look normal but on the inside, I was spinning with questions and uncertainty about my future.

Our CEO and founder Kasper Roet (r) led a Termeer Foundation fireside chat with Massachusetts Institute of Technology (MIT) professor Jonathan Fleming (l), QurAlis advisor, early investor & former board chair, and Kristina Masson, CEO of Acrivon AB. #ALS #precisionmedicine #neurodegenerativediseases

QurAlis presents! Vikas Sharma, QurAlis' chief business officer, recently presented a corporate update at the #BioFuture2023 conference. #ALS #precisionmedicine #neurodegenerativediseases

QurAlis' CEO and founder Kasper Roet was an invited speaker on the 2023 William Blair Innovator Series: Genetic Medicines panel, "Combining Novel Genetics and Modalities to Tackle Neurodegenerative Disorders." #ALS #precisionmedicine #neurodegenerativediseases

QurAlis presents! CEO & founder Kasper Roet recently presented a corporate overview and update at the Piper Sandler 35th Annual Healthcare Conference. #ALS #FTD #precisionmedicine #neurodegenerativediseases